Dose-dense Chemotherapy for Aggressive Non-Hodgkin Lymphoma
Current status of dose-dense chemotherapy for breast cancer | SpringerLink
A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma - European Journal of ...
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - Annals of Oncology
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer
Dose dense chemotherapy in the adjuvant treatment of ovarian cancer - ppt download
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
Current status of dose-dense chemotherapy for breast cancer | SpringerLink
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Dose-Dense Chemotherapy – Callaix
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? - Annals of Oncology
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis - Xiu - 2022 -
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort
